Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Seagen Inc (SGEN)

Seagen Inc (SGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Seagen Inc 21823 30TH DRIVE SE SUITE BOTHELL WA 98021 USA

www.seagen.com P: 425-527-4000 F: 425-527-4001

Description:

Seagen, Inc., a biotechnology company, focuses on developing & commercializing therapies targeted for the treatment of cancer. Adcetris, a lead FDA approved marketed product at Seagen, is used for treating Hodgkin lymphoma, certain T-cell lymphomas, other cancers in the U.S., Europe & several countries. Seagen has an agreement with Takeda Pharmaceutical Company Ltd. for the further development and commercialization of Adcetris. Seagen retains all rights to sell Adcetris in the U.S. and Canada, while Takeda has commercial rights to the drug in the rest of the world. The FDA granted approvals to Seagen's several drugs named Padcev, for treating advanced/metastatic urothelial cancer; Tukysa and Tivdak for treating adult patients with locally advanced/metastatic HER2-positive breast cancer and for the treatment of recurrent/metastatic cervical cancer in adult patients respectively. The company also has license agreements with partners like Merck, Roche, GlaxoSmithKline, Astellas, AbbVie, Bristol-Myers and Genmab.

Key Statistics

Overview:

Market Capitalization, $K 42,934,040
Enterprise Value, $K 42,614,100
Shares Outstanding, K 187,698
Annual Sales, $ 1,962 M
Annual Net Income, $ -610,310 K
Last Quarter Sales, $ 648,650 K
Last Quarter Net Income, $ -215,790 K
EBIT, $ -790,570 K
EBITDA, $ -715,480 K
60-Month Beta 0.32
% of Insider Shareholders 25.90%
% of Institutional Shareholders 84.26%
Float, K 139,084
% Float 74.10%
Short Volume Ratio 0.50

Growth:

1-Year Return 70.63%
3-Year Return 13.72%
5-Year Return 336.44%
5-Year Revenue Growth 306.93%
5-Year Earnings Growth -275.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.15 on 11/01/23
Next Earnings Date N/A
Earnings Per Share ttm -4.01
EPS Growth vs. Prev Qtr -1.77%
EPS Growth vs. Prev Year -11.65%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

SGEN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -28.06%
Return-on-Assets % -20.92%
Profit Margin % -31.10%
Debt/Equity 0.00
Price/Sales 21.89
Price/Cash Flow N/A
Price/Book 16.92
Book Value/Share 13.52
Interest Coverage -0.27
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar